Details of the Drug
General Information of Drug (ID: DM78UPQ)
Drug Name |
1,3-Bis-(3-imidazolidin-2-yl-phenyl)-urea
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Imidocarb; 27885-92-3; Imidocarbum; Imidocarbe; Imidocarbo; 1,3-bis[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]urea; Imidocarb [INN:BAN]; UNII-8USS3K0VDH; Imidocarbum [INN-Latin]; Imidocarbe [INN-French]; Imidocarbo [INN-Spanish]; 1,3-Bis(3-(2-imidazolin-2-yl)phenyl)urea; 1,3-Bis(3-(2-imidazolin-2-yl)phenyl)harnstoff; C19H20N6O; TCMDC-124304; N,N'-Bis(3-(4,5-dihydro-1H-imidazol-2-yl)phenyl)urea; EINECS 248-711-7; 8USS3K0VDH; CARBANILIDE, 3,3'-DI-2-IMIDAZOLIN-2-YL-; BRN 0964732; CHEMBL427342; NSC 51189; Urea, N,N'-bis[3-(4,5-dihydro-
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 348.4 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 0.4 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 4 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 4 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||